Piribo: Financial Markets Research: Santarus, Inc.'s Zegerid, new publication announcement

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “Financial Markets Research: Santarus, Inc.'s Zegerid - Fast-acting formulation gaining momentum in GERD”. http://www.piribo.com/publications/finance_investment/financial_markets_research_santarus_incs_zegerid.html

Following the lackluster 2004 launch of an oral suspension formulation of Santarus' lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus' future success is tied to the commercial potential for the recently launched Zegerid oral capsule formulation to drive near-term revenues.

Highlights
Despite a very competitive prescription PPI landscape, we believe that Zegerid's rapid absorption profile and data supporting its use in patients with nocturnal breakthrough GERD symptoms should provide Santarus and its marketing partner Otsuka with a relatively compelling marketing message for physicians.As a result, we forecast US Zegerid revenues slightly ahead of Wall Street consensus.

Scope
- Analyzes the commercial potential for Santarus' Zegerid capsule, the first fast-acting capsule PPI to be approved the US FDA
- Datamonitor interviewed eight gastroenterologists and primary care physicians familiar with the Zegerid oral capsule in the course of research
Reasons to Purchase
- Understand the commercial potential for Santarus' Zegerid through in-depth analysis based on interviews with leading experts
- Anticipate likely changes in the future market dynamics for GERD therapies following the likely success of Zegerid

Contents
Summary
Santarus, Inc.
Gastroesophageal Reflux Disease
Factors Affecting The Potential For Santarus' Zegerid
Datamonitor Zegerid Forecast
Appendix

“Financial Markets Research: Santarus, Inc.'s Zegerid - Fast-acting formulation gaining momentum in GERD” is available from Piribo. For more information go to: http://www.piribo.com/publications/finance_investment/financial_markets_research_santarus_incs_zegerid.html

Piribo Product ID: DAT549

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.